Return to Today's science sparks archives

Information Click the tweet icon above each article title to share it on Twitter.

2010-07-01

Fig 1. Hierarchical unsupervised clustering was performed using Partek® Genomics SuiteTM across all genes present on the Affymetrix U133A chip.

Fig 1. Hierarchical unsupervised clustering was performed using Partek® Genomics SuiteTM across all genes present on the Affymetrix U133A chip.
  • Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan ML, Antonescu CR

  • J Pathol. 2010 Jul;221(3):300-7.

2010-06-30

Fig 7. Focal induction of ICAM-1 mediates targeting of Ly6C-high monocytes.

Fig 7. Focal induction of ICAM-1 mediates targeting of Ly6C-high monocytes.
  • Shi C, Velázquez P, Hohl TM, Leiner I, Dustin ML, Pamer EG

  • J Immunol. 2010 Jun 1;184(11):6266-74.

2010-06-29

Fig 9a. 4-year-old boy with stage IV neuroblastoma who presented with hemorrhagic left frontal lobe lesion marked by fluid–fluid level (arrows) and peripheral rim of enhancement.

Fig 9a. 4-year-old boy with stage IV neuroblastoma who presented with hemorrhagic left frontal lobe lesion marked by fluid–fluid level (arrows) and peripheral rim of enhancement.
  • D'Ambrosio N, Lyo JK, Young RJ, Haque SS, Karimi S

  • AJR Am J Roentgenol. 2010 May;194(5):1223-9.

2010-06-28

Figure 2. Examples of common abnormalities noted on computed tomographic scans following diagnosis of uveal melanoma.

Figure 2. Examples of common abnormalities noted on computed tomographic scans following diagnosis of uveal melanoma.
  • Feinstein EG, Marr BP, Winston CB, Abramson DH

  • Arch Ophthalmol. 2010 Mar;128(3):319-23.

2010-06-25

(A) Axial cardiac computed tomography (CT) demonstrating a plaque in the right coronary artery (RCA).

(A) Axial cardiac computed tomography (CT) demonstrating a plaque in the right coronary artery (RCA).
  • Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, Tahara N, Fuster V, Warburton EA, Fayad ZA, Tawakol AA

  • J Am Coll Cardiol. 2010 Jun 8;55(23):2527-35.

2010-06-24

Fig 2. NBI of a lesion after BCG-therapy.

Fig 2. NBI of a lesion after BCG-therapy.
  • Herr H, Donat M, Dalbagni G, Taylor J

  • BJU Int. 2010 Jul;106(1):53-5.

2010-06-23

Fig 1. p95HER2 staining in breast tumors.

Fig 1. p95HER2 staining in breast tumors.
  • Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, Baselga J

  • Clin Cancer Res. 2010 May 1;16(9):2688-95.

2010-06-22

Fig 2. Representation of nanomaterials with comparison to biologics, drawn to scale.

Fig 2. Representation of nanomaterials with comparison to biologics, drawn to scale.
  • Scheinberg DA, Villa CH, Escorcia FE, McDevitt MR

  • Nat Rev Clin Oncol. 2010 May;7(5):266-76.

2010-06-21

Fig 2. Low-power whole-mount radical prostatectomy specimens showing a multifocal prostate cancer not considered suitable for focal therapy.

Fig 2. Low-power whole-mount radical prostatectomy specimens showing a multifocal prostate cancer not considered suitable for focal therapy.
  • Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S

  • Eur Urol. 2010 July 2010;58(1):57-64.

2010-06-18

Fig 4. Neck levels included in a supraomohyoid neck dissection— Levels IA, IB, IIA, IIB, III.

Fig 4. Neck levels included in a supraomohyoid neck dissection— Levels IA, IB, IIA, IIB, III.
  • Liu JC, Shah JP

  • J Surg Oncol. 2010 Jun 15;101(8):661-8.

2010-06-17

Fig 1. miR-504 Negatively Regulates p53 Protein Levels in Cells(A)

Fig 1. miR-504 Negatively Regulates p53 Protein Levels in Cells(A)
  • Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng Z

  • Mol Cell. 2010 Jun 11;38(5):689-99.

2010-06-16

Fig 2. Differential in vivo antitumor potency of tumor-specific human primary T cells overexpressing IL-2, IL-7, IL-15, or IL-21.

Fig 2. Differential in vivo antitumor potency of tumor-specific human primary T cells overexpressing IL-2, IL-7, IL-15, or IL-21.
  • Markley JC, Sadelain M

  • Blood. 2010 Apr 29;115(17):3508-19.

2010-06-15

Fig 2. Predicted 8-year probability of metastases by preoperative nomogram risk, separately by treatment.

Fig 2. Predicted 8-year probability of metastases by preoperative nomogram risk, separately by treatment.
  • Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A, Scardino PT

  • J Clin Oncol. 2010 Mar 20;28(9):1508-13.

2010-06-14

Fig 1. A synergistic balance between Shh signaling and mTOR activity.

Fig 1. A synergistic balance between Shh signaling and mTOR activity.
  • Bhatia B, Nahlé Z, Kenney AM

  • Cell Cycle. 2010 Feb;9(3):456-9.

2010-06-11

Fig 2. Total and phospho-Rb staining in skin biopsies.

Fig 2. Total and phospho-Rb staining in skin biopsies.
  • Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JH, Shapiro GI

  • Ann Oncol. 2010 Apr;21(4):884-94.

2010-06-10

Fig 2. Perivascular infiltration of cells into tumor tissues after treatment with 10 mg/kg/dose of anti–CTLA-4.

Fig 2. Perivascular infiltration of cells into tumor tissues after treatment with 10 mg/kg/dose of anti–CTLA-4.
  • Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P

  • Clin Cancer Res. 2010 May 15;16(10):2861-71.

2010-06-09

Fig 4. Confirmation of the t(4;6) positive cells using split signal approach.

Fig 4. Confirmation of the t(4;6) positive cells using split signal approach.
  • Shan L, Ambroisine L, Clark J, Yáñez-Muñoz RJ, Fisher G, Kudahetti SC, Yang J, Kia S, Mao X, Fletcher A, Flohr P, Edwards S, Attard G, De-Bono J, Young BD, Foster CS, Reuter V, Moller H, Oliver TD, Berney DM, Scardino P, Cuzick J, Cooper CS, Lu YJ; Transatlantic Prostate Group

  • Prostate Cancer Prostatic Dis. 2010 Jun;13(2):117-25.

2010-06-08

Fig 1. Overview of oncolytic HSV-1 structure and generations.

Fig 1. Overview of oncolytic HSV-1 structure and generations.
  • Carpenter SG, Carson J, Fong Y

  • Semin Oncol. 2010 Apr;37(2):160-9.

2010-06-07

Fig 3. PlagL2 Promotes NSC/Progenitor Cell Proliferation by Attenuating Its Differentiation.

Fig 3. PlagL2 Promotes NSC/Progenitor Cell Proliferation by Attenuating Its Differentiation.
  • Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, Hu J, Vinjamoori A, Gan B, Sahin E, Chheda MG, Brennan C, Wang YA, Hahn WC, Chin L, DePinho RA

  • Cancer Cell. 2010 May 18;17(5):497-509.

2010-06-04

Fig 2. Waterfall plot of percentage change in prostate-specific antigen (PSA) from baseline.

Fig 2. Waterfall plot of percentage change in prostate-specific antigen (PSA) from baseline.
  • Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium.

  • Lancet. 2010 Apr 24;375(9724):1437-46.

2010-06-03

Fig 1. (a) Kaplan-Meier estimates for recurrence-free survival; (b) cancer-specific survival in 1249 patients managed by radical nephroureterectomy for upper tract urothelial carcinoma.

Fig 1. (a) Kaplan-Meier estimates for recurrence-free survival; (b) cancer-specific survival in 1249 patients managed by radical nephroureterectomy for upper tract urothelial carcinoma.
  • Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF

  • Eur Urol. 2009 Jul 15.

2010-06-02

Fig 4c. Stratification of the gene datasets upregulated in Ptenhy/+ MEFs according to GO-BP.

Fig 4c. Stratification of the gene datasets upregulated in Ptenhy/+ MEFs according to GO-BP.
  • Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP

  • Nat Genet. 2010 May;42(5):454-8.

2010-06-01

Fig 2. Irradiated (A) and normal (B) vocal fold histology (trichrome; original magnification ×40) after 40 Gy exposure (4 Gy × 10 days).

Fig 2. Irradiated (A) and normal (B) vocal fold histology (trichrome; original magnification ×40) after 40 Gy exposure (4 Gy × 10 days).
  • Saltman B, Kraus DH, Szeto H, Parashar B, Ghossein R, Felsen D, Branski RC

  • Head Neck. 2010 May;32(5):572-7.

2010-05-28

Fig 2. Ultraviolet B irradiances in Miami, FL, (A) and Boston, MA, (B) at different times of day and seasons.

Fig 2. Ultraviolet B irradiances in Miami, FL, (A) and Boston, MA, (B) at different times of day and seasons.
  • Terushkin V, Bender A, Psaty EL, Engelsen O, Wang SQ, Halpern AC

  • J Am Acad Dermatol. 2010 Jun;62(6):929.

2010-05-27

Fig 7. A Model for the RSC/Nucleosome Complex.

Fig 7. A Model for the RSC/Nucleosome Complex.
  • Floer M, Wang X, Prabhu V, Berrozpe G, Narayan S, Spagna D, Alvarez D, Kendall J, Krasnitz A, Stepansky A, Hicks J, Bryant GO, Ptashne M

  • Cell. 2010 Apr 30;141(3):407-18.

2010-05-26

Fig 1. Schematic representation of the TVTC chemotherapy schedule.

Fig 1. Schematic representation of the TVTC chemotherapy schedule.
  • Steinherz PG, Shukla N, Kobos R, Steinherz L

  • Pediatr Blood Cancer. 2010 May;54(5):687-93.

2010-05-25

Fig 4. MS identification of PSA bands in gels depicted as it was determined by MALDI-MS data in peptide mass fingerprint search in the NCBInr database.

Fig 4. MS identification of PSA bands in gels depicted as it was determined by MALDI-MS data in peptide mass fingerprint search in the NCBInr database.
  • Végvári A, Rezeli M, Welinder C, Malm J, Lilja H, Marko-Varga G, Laurell T

  • J Proteomics. 2010 Apr 18;73(6):1137-47.

2010-05-24

Scheme 21.

Scheme 21.
  • Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J

  • J Med Chem. 2010 Apr 8;53(7):2779-96.

2010-05-21

Fig 2.Two secondary structures for the 5S rRNA from the Archaeon, Haloarcula japonica.

Fig 2.Two secondary structures for the 5S rRNA from the Archaeon, Haloarcula japonica.
  • Agius P, Bennett KP, Zuker M

  • RNA. 2010 May;16(5):865-78.

2010-05-20

Fig 1. Mean number of lymph nodes (#LNS) excised by tumor size category is shown with standard error bars. Ax Non-SLN indicates axillary nonsentinel lymph node; Prop, prophylactic mastectomy; DCIS, ductal carcinoma in situ.

Fig 1. Mean number of lymph nodes (#LNS) excised by tumor size category is shown with standard error bars. Ax Non-SLN indicates axillary nonsentinel lymph node; Prop, prophylactic mastectomy; DCIS, ductal carcinoma in situ.
  • Port ER, Patil S, Stempel M, Morrow M, Cody HS 3rd

  • Cancer. 2010 Apr 15;116(8):1987-91.

2010-05-19

Fig 4. Nonspecific pancreatitis with dilated pancreatic ducts and dense interstitial inflammation.

Fig 4. Nonspecific pancreatitis with dilated pancreatic ducts and dense interstitial inflammation.
  • Dhall D, Suriawinata AA, Tang LH, Shia J, Klimstra DS

  • Hum Pathol. 2010 May;41(5):643-52.

2010-05-18

Fig. 1. Myofibers in a variety of model systems form from the fusion of mononucleated muscle precursors. (A–D) Nuclei were visualized using a nuclear DsRed transgene (red) (A), DAPI (blue) (B, C) or hematoxylin (purple) (D).

Fig. 1. Myofibers in a variety of model systems form from the fusion of mononucleated muscle precursors. (A–D) Nuclei were visualized using a nuclear DsRed transgene (red) (A), DAPI (blue) (B, C) or hematoxylin (purple) (D).
  • Rochlin K, Yu S, Roy S, Baylies MK

  • Dev Biol. 2010 May 1;341(1):66-83.

2010-05-17

Fig 4. Dicer is required for sensory nervous system survival but not neuronal differentiation.

Fig 4. Dicer is required for sensory nervous system survival but not neuronal differentiation.
  • Zehir A, Hua LL, Maska EL, Morikawa Y, Cserjesi P

  • Dev Biol. 2010 Apr 15;340(2):459-67.

2010-05-14

Fig 1. Targets in esophagogastic cancers.

Fig 1. Targets in esophagogastic cancers.
  • Ku GY, Ilson DH

  • Cancer Treat Rev. 2010 May;36(3):235-48.

2010-05-12

Fig 1. ROS, IDH1/2 mutations, and iron chelation therapy in normal and leukemic hematopoiesis.

Fig 1. ROS, IDH1/2 mutations, and iron chelation therapy in normal and leukemic hematopoiesis.
  • Abdel-Wahab O, Levine RL

  • J Exp Med. 2010 Apr 12;207(4):677-80.

2010-05-11

Fig 1. γ-Secretase processes a wide range of substrates including the amyloid precursor protein (APP), 1 Notch, ErbB4, nectin 1α, N-cadherin, and other type I transmembrane proteins, reflecting the multitude of physiological functions of this protease.

Fig 1. γ-Secretase processes a wide range of substrates including the amyloid precursor protein (APP), 1 Notch, ErbB4, nectin 1α, N-cadherin, and other type I transmembrane proteins, reflecting the multitude of physiological functions of this protease.
  • Placanica L, Chien JW, Li YM

  • Biochemistry. 2010 Apr 6;49(13):2796-804.

2010-05-10

Fig 1D. Mig-6 is deleted in GBM cell lines and tumor samples. mRNA level of Mig-6 in NHA and GBM cell lines.

Fig 1D. Mig-6 is deleted in GBM cell lines and tumor samples. mRNA level of Mig-6 in NHA and GBM cell lines.
  • Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen AJ, Paik JH, Segatto O, Brennan C, Elferink LA, Wang YA, Chin L, DePinho RA

  • Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6912-7.

2010-05-07

Fig 3. H+E staining of bone marrow, spleen, and liver, and reticulin of hMPLWT mice and hMPLW515L mice treated with vehicle or INCB16562 for 12 days.

Fig 3. H+E staining of bone marrow, spleen, and liver, and reticulin of hMPLWT mice and hMPLW515L mice treated with vehicle or INCB16562 for 12 days.
  • Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL

  • Blood. 2010 Apr 8;115(14):2919-27.

2010-05-05

Fig 1. Example of a poorly differentiated (Gleason 4 + 5 = 9) prostate adenocarcinoma in a 76-yr-old carrier of a BRCA2 mutation.

Fig 1. Example of a poorly differentiated (Gleason 4 + 5 = 9) prostate adenocarcinoma in a 76-yr-old carrier of a BRCA2 mutation.
  • Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V, Zelefsky M, Morris MJ, Scher HI, Klein RJ, Norton L, Eastham JA, Scardino PT, Robson ME, Offit K

  • Clin Cancer Res. 2010 Apr 1;16(7):2115-21.

2010-05-04

Fig 1. ELISA with sera from 60 pancreatic cancer patients, 53 healthy donors, and 51 ovarian cancer patients.

Fig 1. ELISA with sera from 60 pancreatic cancer patients, 53 healthy donors, and 51 ovarian cancer patients.
  • Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen YT, Andrews C, Ritter G, Old LJ, Odunsi K, Jäger D

  • Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5088-93.

2010-05-03

Fig 1. Immunohistochemical staining for Ki67.

Fig 1. Immunohistochemical staining for Ki67.
  • Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J

  • Am J Surg Pathol. 2010 Mar;34(3):300-13.

2010-04-30

Cancer pain guidelines.

Cancer pain guidelines.
  • Dulko D, Hertz E, Julien J, Beck S, Mooney K

  • J Am Acad Nurse Pract. 2010 Jan;22(1):45-55.

2010-04-29

Fig 2. Event-free survival of intent to treat cohort.

Fig 2. Event-free survival of intent to treat cohort.
  • Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, Kewalramani T, Moskowitz AJ, Rice RD, Maragulia J, Vanak J, Trippett T, Hamlin P, Horowitz S, Noy A, O'Connor OA, Portlock C, Straus D, Nimer SD

  • Br J Haematol. 2010 Jan 18.

2010-04-28

Fig 2g. Immunohistochemical staining for Thr202- and Tyr204-phosphorylated Erk1/2 (pErk1/2) in wild-type or Dok3 knockout lung tissue, showing predominantly nuclear staining. Scale bars, 200 μm (left panels), 50 μm (middle panels) or 10 μm (right panels). Arrowhead indicates positive staining in the lung tumor region.

Fig 2g. Immunohistochemical staining for Thr202- and Tyr204-phosphorylated Erk1/2 (pErk1/2) in wild-type or Dok3 knockout lung tissue, showing predominantly nuclear staining. Scale bars, 200 μm (left panels), 50 μm (middle panels) or 10 μm (right panels). Arrowhead indicates positive staining in the lung tumor region.
  • Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP

  • Nat Genet. 2010 Mar;42(3):216-23.

2010-04-27

Fig. 1 Pathophysiology of acute GVHD and GVT effects.

Fig. 1 Pathophysiology of acute GVHD and GVT effects.
  • Jenq RR, van den Brink MR

  • Nat Rev Cancer. 2010 Mar;10(3):213-21.

2010-04-26

Fig 5. The effect of varying dosing frequency on the evolution of resistance.

Fig 5. The effect of varying dosing frequency on the evolution of resistance.
  • Foo J, Michor F

  • J Theor Biol. 2010 Mar 21;263(2):179-88.

2010-04-23

Fig 2: Mad2 overexpression increases aneuploidy but is not enough to overcome oncogene addiction.

Fig 2: Mad2 overexpression increases aneuploidy but is not enough to overcome oncogene addiction.
  • Sotillo R, Schvartzman JM, Socci ND, Benezra R

  • Nature. 2010 Mar 18;464(7287):436-40.

2010-04-22

Fig 2. Process and/or flow or approaches for determination of phase II trial design recommendations. PRO, patient related outcomes; PFS, progression-free survival.

Fig 2. Process and/or flow or approaches for determination of phase II trial design recommendations. PRO, patient related outcomes; PFS, progression-free survival.
  • Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D

  • Clin Cancer Res. 2010 Mar 15;16(6):1764-9.

2010-04-21

Fig 4. Dose distribution comparison between volumetric modulated arc therapy (VMAT) and intensity-modulated radiotherapy (IMRT).

Fig 4. Dose distribution comparison between volumetric modulated arc therapy (VMAT) and intensity-modulated radiotherapy (IMRT).
  • Zhang P, Happersett L, Hunt M, Jackson A, Zelefsky M, Mageras G

  • Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1456-62.

2010-04-20

Fig 3. miR-9 induces angiogenesis, mesenchymal marker expression and metastasis of the SUM149 epithelial tumours.

Fig 3. miR-9 induces angiogenesis, mesenchymal marker expression and metastasis of the SUM149 epithelial tumours.
  • Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA

  • Nat Cell Biol. 2010 Mar;12(3):247-56.

2010-04-19

Fig 1. miR-29a is expressed at high levels in human HSCs as well as human AML.

Fig 1. miR-29a is expressed at high levels in human HSCs as well as human AML.
  • Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, Liu M, Zou Y, Weissman IL, Gu H

  • J Exp Med. 2010 Mar 15;207(3):475-89.

2010-04-16

Fig 1. Association of Tie1 and -2 on the Cell Surface as Analyzed by the FRET-Based Spatial Proximity Assay.

Fig 1. Association of Tie1 and -2 on the Cell Surface as Analyzed by the FRET-Based Spatial Proximity Assay.
  • Seegar TC, Eller B, Tzvetkova-Robev D, Kolev MV, Henderson SC, Nikolov DB, Barton WA

  • Mol Cell. 2010 Mar 12;37(5):643-55.

2010-04-15

Fig 2. A, PSM learning curve by each surgeon with at least 250 cases.

Fig 2. A, PSM learning curve by each surgeon with at least 250 cases.
  • Vickers A, Bianco F, Cronin A, Eastham J, Klein E, Kattan M, Scardino P

  • J Urol. 2010 Apr;183(4):1360-5

2010-04-13

Fig 6. Structural Modeling of R140Q Mutant IDH2.

Fig 6. Structural Modeling of R140Q Mutant IDH2.
  • Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB

  • Cancer Cell. 2010 Mar 16;17(3):225-34.

2010-04-12

Fig 1c. Comparison of CD34+ cell viability using modified and traditional gating in CB units with a small percentage of dead cells. The difference between the 2 gating strategies is small.

Fig 1c. Comparison of CD34+ cell viability using modified and traditional gating in CB units with a small percentage of dead cells. The difference between the 2 gating strategies is small.
  • Scaradavou A, Smith KM, Hawke R, Schaible A, Abboud M, Kernan NA, Young JW, Barker JN

  • Biol Blood Marrow Transplant. 2010 Apr;16(4):500-8.

2010-04-09

Fig 1. Association results, recombination and linkage disequilibrium plots for 13q22.1, 1q32.1 and 5p15.33.

Fig 1. Association results, recombination and linkage disequilibrium plots for 13q22.1, 1q32.1 and 5p15.33.
  • Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF Jr, Hoover RN, Hartge P, Chanock SJ

  • Nat Genet. 2010 Mar;42(3):224-8.

2010-04-08

Fig 7. The survival time after diagnosis with treatment.

Fig 7. The survival time after diagnosis with treatment.
  • Haeno H, Michor F

  • J Theor Biol. 2010 Mar 7;263(1):30-44.

2010-04-06

Fig 5. Medium magnification of SSO (case 5) composed of fatty tissue intermixed with multiple areas of cartilaginous cap formation overlying central areas of ossification.

Fig 5. Medium magnification of SSO (case 5) composed of fatty tissue intermixed with multiple areas of cartilaginous cap formation overlying central areas of ossification.
  • Veras E, Abadeer R, Khurana H, Tan D, Ayala A

  • Ann Diagn Pathol. 2010 Apr;14(2):94-9.

2010-04-05

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia
  • O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M; National Comprehensive Cancer Network

  • J Natl Compr Canc Netw. 2009 Oct;7(9):984-1023.

2010-04-02

Fig 1. Antigen Expression in 18 Treated Patients.

Fig 1. Antigen Expression in 18 Treated Patients.
  • Lechowicz M, Dittmer DP, Lee JY, Krown SE, Wachsman W, Aboulafia D, Dezube BJ, Ratner L, Said J, Ambinder RF

  • Clin Infect Dis. 2009 Dec 15;49(12):1946-9.

2010-04-01

Fig 3. Constitutive expression of Def does not rescue Dif dl hemocyte phenotypes.

Fig 3. Constitutive expression of Def does not rescue Dif dl hemocyte phenotypes.
  • Matova N, Anderson KV

  • J Cell Sci. 2010 Feb 15;123(Pt 4):627-33.